# Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

> **NCT00528242** · PHASE2 · COMPLETED · sponsor: **Response Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Raynaud's Disease

## Interventions

- **DRUG:** SLx-2101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00528242
- **Lead sponsor:** Response Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528242, "Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00528242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*